Interim Unaudited Financial Statements

For the Six-Month Period Ended September 30, 2024

These Interim Unaudited Financial Statements do not contain the Interim Management Report of Fund Performance ("MRFP") of the investment fund. You may obtain a copy of the Interim MRFP, at no cost, by contacting us using one of the methods noted under Fund Formation and Series Information or by visiting the SEDAR+ website at www.sedarplus.ca. Copies of the Annual Financial Statements or Annual MRFP may also be obtained, at no cost, using any of the methods outlined above.

Securityholders may also contact us using one of these methods to request a copy of the investment fund's proxy voting policies and procedures, proxy voting disclosure record or quarterly portfolio disclosure.

NOTICE OF NO AUDITOR REVIEW OF THE INTERIM FINANCIAL STATEMENTS

Mackenzie Financial Corporation, the Manager of the Mackenzie US Small-Mid Cap Growth Fund (the "Fund"), appoints independent auditors to audit the Fund's Annual Financial Statements. Under Canadian securities laws (National Instrument 81-106), if an auditor has not reviewed the Interim Financial Statements, this must be disclosed in an accompanying notice.

The Fund's independent auditors have not performed a review of these Interim Financial Statements in accordance with standards established by the Chartered Professional Accountants of Canada.



INTERIM UNAUDITED FINANCIAL STATEMENTS | September 30, 2024

STATEMENTS OF FINANCIAL POSITION

at (in \$ 000 except per security amounts)

	Sep. 30 2024	Mar. 31 2024 (Audited)
	\$	\$
ASSETS		
Current assets		
Investments at fair value	2,802,273	2,958,589
Cash and cash equivalents	106,507	110,681
Dividends receivable	456	914
Accounts receivable for investments sold	827	2,239
Accounts receivable for securities issued	366	1,747
Due from manager	5	784
Taxes recoverable	-	2,500
Total assets	2,910,434	3,077,454
LIABILITIES		
Current liabilities		
Accounts payable for investments purchased	_	1,031
Accounts payable for securities redeemed	1,344	5,067
Due to manager	404	428
Total liabilities	1,748	6,526
Net assets attributable to securityholders	2,908,686	3,070,928

	Net assets attributable to securityholders (note 3)							
	per sec	curity	per s	eries				
		Mar. 31		Mar. 31				
	Sep. 30	2024	Sep. 30	2024				
	2024	(Audited)	2024	(Audited)				
Series A	53.61	51.97	557,378	606,014				
Series AR	20.93	20.29	35,762	37,736				
Series B	28.22	27.32	93	169				
Series D	20.05	19.32	23,563	24,225				
Series F	60.29	58.00	1,200,538	1,291,704				
Series F5	14.59	14.37	7,112	7,755				
Series F8	11.82	11.82	7,435	8,012				
Series FB	16.13	15.54	2,816	1,695				
Series FB5	13.34	13.17	14	14				
Series I	58.44	56.42	2,153	2,307				
Series J	28.83	27.91	375	363				
Series M	63.77	61.47	2,598	2,572				
Series 0	60.73	58.12	50,022	50,977				
Series PW	20.86	20.18	814,308	835,007				
Series PWFB	13.69	13.17	28,628	21,658				
Series PWFB5	13.40	13.20	393	386				
Series PWR	11.28	10.91	22,681	19,581				
Series PWT5	13.43	13.31	17,862	19,526				
Series PWT8	12.18	12.25	16,065	17,545				
Series PWX	22.41	21.44	10,938	12,227				
Series PWX8	12.28	12.21	731	730				
Series T5	21.27	21.11	5,547	6,676				
Series T8	15.46	15.58	4,360	5,272				
Series UM	10.65	10.24	2,103	1,680				
Series LB	28.46	27.60	11,923	13,481				
Series LF	11.91	11.46	27,252	25,424				
Series LW	13.15	12.73	56,036	58,192				
			2,908,686	3,070,928				

INTERIM UNAUDITED FINANCIAL STATEMENTS | September 30, 2024

STATEMENTS OF COMPREHENSIVE INCOME

	2024 \$	2023 \$
Income	Ψ	Ψ
Dividends	3.211	6,523
Interest income for distribution purposes	2,577	2,108
Other changes in fair value of investments and other	_,~~	2,200
net assets		
Net realized gain (loss)	115,267	(188,678)
Net unrealized gain (loss)	5,204	155,683
Securities lending income	25	5
Total income (loss)	126,284	(24,359)
Expenses (note 6)		
Management fees	22,179	23,230
Management fee rebates	(25)	(44)
Administration fees	2,874	3,030
Interest charges	3	1
Commissions and other portfolio transaction costs	813	902
Independent Review Committee fees	5	5
Expenses before amounts absorbed by Manager	25,849	27,124
Expenses absorbed by Manager	_	
Net expenses	25,849	27,124
Increase (decrease) in net assets attributable to		
securityholders from operations before tax	100,435	(51,483)
Foreign withholding tax expense (recovery)	482	978
Foreign income tax expense (recovery)	-	
Increase (decrease) in net assets attributable to		
securityholders from operations	99,953	(52,461)

		Increase (decrease) in net assets attributable to securityholders from operations (note 3)							
	per sec	urity	per s	eries					
	2024	2023	2024	2023					
Series A	1.54	(0.97)	16,968	(13,389)					
Series AR	0.61	(0.38)	1,079	(759)					
Series B	0.70	(0.54)	4	(4)					
Series D	0.71	(0.43)	857	(415)					
Series F	2.12	(0.70)	44,576	(17,833)					
Series F5	0.53	(0.21)	277	(103)					
Series F8	0.45	(0.14)	293	(119)					
Series FB	1.23	(0.23)	241	(35)					
Series FB5	0.49	(0.19)	-	_					
Series I	1.91	(0.84)	71	(37)					
Series J	0.92	(0.50)	12	(6)					
Series M	2.33	(0.44)	97	(32)					
Series 0	2.57	(0.38)	2,134	(391)					
Series PW	0.65	(0.35)	26,161	(15,704)					
Series PWFB	0.65	(0.15)	1,322	(276)					
Series PWFB5	0.51	(0.17)	15	(5)					
Series PWR	0.39	(0.19)	752	(318)					
Series PWT5	0.41	(0.23)	555	(376)					
Series PWT8	0.38	(0.22)	516	(342)					
Series PWX	0.94	(0.15)	495	(96)					
Series PWX8	0.53	(0.10)	33	(6)					
Series T5	0.57	(0.40)	158	(157)					
Series T8	0.42	(0.30)	129	(147)					
Series UM	0.44	(0.15)	74	(22)					
Series LB	0.79	(0.52)	354	(302)					
Series LF	0.43	(0.15)	983	(356)					
Series LW	0.41	(0.22)	1,797	(1,231)					
<u> </u>			99,953	(52,461)					

INTERIM UNAUDITED FINANCIAL STATEMENTS | September 30, 2024

STATEMENTS OF CHANGES IN FINANCIAL POSITION

	Tot	tal	Serie	s A	Series AR		Series B		Series	5 D
	2024	2023	2024	2023	2024	2023	2024	2023	2024	2023
NET ASSETS ATTRIBUTABLE TO SECURITYHOLDERS										
Beginning of period	3,070,928	3,225,713	606,014	673,651	37,736	36,241	169	230	24,225	14,914
Increase (decrease) in net assets from operations	99,953	(52,461)	16,968	(13,389)	1,079	(759)	4	(4)	857	(415)
Distributions paid to securityholders:										
Investment income	-	-	_	-	-	-	_	-	-	-
Capital gains	_	-	_	-	_	-	_	-	_	-
Return of capital	(1,891)	(2,298)	_	-	_	-	_	-	_	-
Management fee rebates	(25)	(44)	(1)	(3)				_		
Total distributions paid to securityholders	(1,916)	(2,342)	(1)	(3)				_		
Security transactions:										
Proceeds from securities issued	233,502	116,920	31,067	19,129	2,274	1,369	_	-	1,583	6,286
Reinvested distributions	698	928	1	2	_	-	_	-	_	-
Payments on redemption of securities	(494,479)	(361,971)	(96,671)	(80,484)	(5,327)	(1,957)	(80)	(32)	(3,102)	(1,214)
Total security transactions	(260,279)	(244,123)	(65,603)	(61,353)	(3,053)	(588)	(80)	(32)	(1,519)	5,072
Increase (decrease) in net assets attributable to securityholders	(162,242)	(298,926)	(48,636)	(74,745)	(1,974)	(1,347)	(76)	(36)	(662)	4,657
End of period	2,908,686	2,926,787	557,378	598,906	35,762	34,894	93	194	23,563	19,571
Increase (decrease) in fund securities (in thousands) (note 7):			Securi	ties	Securi	ties	Securit	ies	Securit	ties
Securities outstanding – beginning of period			11,662	14,429	1,859	1,987	6	9	1,254	870
Issued			598	411	111	76	_	-	82	359
Reinvested distributions			_	-	_	-	_	-	_	-
Redeemed			(1,864)	(1,730)	(262)	(107)	(3)	(1)	(161)	(70)
Securities outstanding – end of period			10,396	13,110	1,708	1,956	3	8	1,175	1,159

	Seri	es F	Series	F5	Series	F8	Series	FB	Series	FB5
	2024	2023	2024	2023	2024	2023	2024	2023	2024	2023
NET ASSETS ATTRIBUTABLE TO SECURITYHOLDERS										
Beginning of period	1,291,704	1,367,220	7,755	6,902	8,012	9,904	1,695	2,247	14	13
Increase (decrease) in net assets from operations	44,576	(17,833)	277	(103)	293	(119)	241	(35)	_	_
Distributions paid to securityholders:										
Investment income	_	_	_	_	_	_	_	_	_	_
Capital gains	_	_	_	_	_	_	_	_	_	_
Return of capital	_	_	(176)	(163)	(293)	(373)	_	_	_	_
Management fee rebates	(4)	(5)	_	_	_	_	_	_	_	_
Total distributions paid to securityholders	(4)	(5)	(176)	(163)	(293)	(373)	_	_	_	_
Security transactions:										
Proceeds from securities issued	115,889	59,712	809	710	140	93	8,815	101	_	_
Reinvested distributions	2	5	56	36	35	59	_	-	_	-
Payments on redemption of securities	(251,629)	(178,058)	(1,609)	(1,129)	(752)	(1,261)	(7,935)	(392)		_
Total security transactions	(135,738)	(118,341)	(744)	(383)	(577)	(1,109)	880	(291)	_	_
Increase (decrease) in net assets attributable to securityholders	(91,166)	(136,179)	(643)	(649)	(577)	(1,601)	1,121	(326)		_
End of period	1,200,538	1,231,041	7,112	6,253	7,435	8,303	2,816	1,921	14	13
Increase (decrease) in fund securities (in thousands) (note 7):	Secu	rities	Securi	ties	Securi	ties	Securi	ties	Secur	ities
Securities outstanding – beginning of period	22,270	26,628	540	516	678	873	109	163	1	1
Issued	1,988	1,160	56	53	12	8	593	7	_	_
Reinvested distributions	_	_	4	3	3	5	_	_	_	_
Redeemed	(4,344)	(3,465)	(113)	(86)	(64)	(113)	(527)	(29)	_	_
Securities outstanding – end of period	19,914	24,323	487	486	629	773	175	141	1	1

INTERIM UNAUDITED FINANCIAL STATEMENTS | September 30, 2024

STATEMENTS OF CHANGES IN FINANCIAL POSITION (cont'd)

	Serie	s I	Series J		Series M		Series 0		Series	PW
	2024	2024 2023		2023	2024	2023	2024	2023	2024	2023
NET ASSETS ATTRIBUTABLE TO SECURITYHOLDERS										
Beginning of period	2,307	2,289	363	325	2,572	4,239	50,977	53,012	835,007	840,208
Increase (decrease) in net assets from operations	71	(37)	12	(6)	97	(32)	2,134	(391)	26,161	(15,704)
Distributions paid to securityholders:										
Investment income	_	-	_	-	-	-	_	-	_	-
Capital gains	_	-	_	-	-	-	_	-	_	-
Return of capital	_	-	_	_	-	-	_	-	_	-
Management fee rebates		_			(2)	(4)		_	(14)	(25)
Total distributions paid to securityholders		_			(2)	(4)		_	(14)	(25)
Security transactions:										
Proceeds from securities issued	31	3	_	-	-	-	4,149	1,351	46,530	23,624
Reinvested distributions	-	-	_	-	2	4	_	-	9	25
Payments on redemption of securities	(256)	(123)			(71)	(909)	(7,238)	(4,621)	(93,385)	(72,788)
Total security transactions	(225)	(120)			(69)	(905)	(3,089)	(3,270)	(46,846)	(49,139)
Increase (decrease) in net assets attributable to securityholders	(154)	(157)	12	(6)	26	(941)	(955)	(3,661)	(20,699)	(64,868)
End of period	2,153	2,132	375	319	2,598	3,298	50,022	49,351	814,308	775,340
Increase (decrease) in fund securities (in thousands) (note 7):	Securi	ties	Securi	ities	Securit	ties	Securi	ties	Securi	ties
Securities outstanding – beginning of period	41	46	13	13	42	78	877	1,041	41,380	46,517
Issued	1	-	_	-	-	-	71	27	2,304	1,309
Reinvested distributions	_	-	_	_	_	-	_	-	_	1
Redeemed	(5)	(3)			(1)	(17)	(124)	(90)	(4,643)	(4,039)
Securities outstanding – end of period	37	43	13	13	41	61	824	978	39,041	43,788

	Series P	WFB	Series P	WFB5	Series PWR		Series PWT5		Series PWT8	
	2024	2023	2024	2023	2024	2023	2024	2023	2024	2023
NET ASSETS ATTRIBUTABLE TO SECURITYHOLDERS										
Beginning of period	21,658	21,791	386	389	19,581	15,607	19,526	21,139	17,545	18,951
Increase (decrease) in net assets from operations	1,322	(276)	15	(5)	752	(318)	555	(376)	516	(342)
Distributions paid to securityholders:										
Investment income	_	-	_	_	_	_	_	_	_	_
Capital gains	_	-	_	_	_	_	_	_	_	_
Return of capital	_	-	(9)	(9)	_	_	(428)	(513)	(638)	(725)
Management fee rebates	(1)	(1)	_	_	_	_	(3)	(5)	_	_
Total distributions paid to securityholders	(1)	(1)	(9)	(9)	_	_	(431)	(518)	(638)	(725)
Security transactions:										
Proceeds from securities issued	8,402	414	_	-	3,393	1,201	967	146	795	377
Reinvested distributions	1	1	2	2	_	_	135	211	282	324
Payments on redemption of securities	(2,754)	(2,212)	(1)	(3)	(1,045)	(588)	(2,890)	(1,410)	(2,435)	(2,061)
Total security transactions	5,649	(1,797)	1	(1)	2,348	613	(1,788)	(1,053)	(1,358)	(1,360)
Increase (decrease) in net assets attributable to securityholders	6,970	(2,074)	7	(15)	3,100	295	(1,664)	(1,947)	(1,480)	(2,427)
End of period	28,628	19,717	393	374	22,681	15,902	17,862	19,192	16,065	16,524
Increase (decrease) in fund securities (in thousands) (note 7):	Securi	ties	Securi	ties	Securi	ties	Securi	ties	Securi	ties
Securities outstanding – beginning of period	1,645	1,869	29	32	1,794	1,597	1,467	1,687	1,433	1,593
Issued	656	36	_	-	311	123	74	12	66	32
Reinvested distributions	_	-	_	-	_	-	10	17	23	28
Redeemed	(210)	(189)		_	(95)	(60)	(221)	(114)	(203)	(177)
Securities outstanding – end of period	2,091	1,716	29	32	2,010	1,660	1,330	1,602	1,319	1,476

INTERIM UNAUDITED FINANCIAL STATEMENTS | September 30, 2024

STATEMENTS OF CHANGES IN FINANCIAL POSITION (cont'd)

	Series I	PWX	Series PWX8		Series	T5	Series T8	
	2024	2023	2024	2023	2024	2023	2024	2023
NET ASSETS ATTRIBUTABLE TO SECURITYHOLDERS								
Beginning of period	12,227	13,004	730	710	6,676	8,235	5,272	7,570
Increase (decrease) in net assets from operations	495	(96)	33	(6)	158	(157)	129	(147)
Distributions paid to securityholders:								
Investment income	_	-	_	-	_	-	_	-
Capital gains	_	-	_	-	_	-	_	-
Return of capital	_	-	(28)	(28)	(139)	(194)	(180)	(293)
Management fee rebates		_		_		(1)		_
Total distributions paid to securityholders		_	(28)	(28)	(139)	(195)	(180)	(293)
Security transactions:								
Proceeds from securities issued	626	197	_	-	738	61	339	156
Reinvested distributions	_	-	_	-	94	137	79	122
Payments on redemption of securities	(2,410)	(1,331)	(4)	(7)	(1,980)	(1,023)	(1,279)	(828)
Total security transactions	(1,784)	(1,134)	(4)	(7)	(1,148)	(825)	(861)	(550)
Increase (decrease) in net assets attributable to securityholders	(1,289)	(1,230)	1	(41)	(1,129)	(1,177)	(912)	(990)
End of period	10,938	11,774	731	669	5,547	7,058	4,360	6,580
Increase (decrease) in fund securities (in thousands) (note 7):	Securi	ties	Securi	ties	Securit	ties	Securit	ies
Securities outstanding – beginning of period	570	692	60	61	316	413	338	498
Issued	30	11	_	-	35	3	23	11
Reinvested distributions	_	-	_	-	5	7	5	8
Redeemed	(112)	(70)		_	(95)	(52)	(84)	(56)
Securities outstanding – end of period	488	633	60	61	261	371	282	461

	Series	UM	Series	LB	Series	LF	Series	LW
	2024	2023	2024	2023	2024	2023	2024	2023
NET ASSETS ATTRIBUTABLE TO SECURITYHOLDERS								
Beginning of period	1,680	1,212	13,481	14,972	25,424	24,285	58,192	66,453
Increase (decrease) in net assets from operations	74	(22)	354	(302)	983	(356)	1,797	(1,231)
Distributions paid to securityholders:								
Investment income	_	-	_	-	_	-	_	-
Capital gains	_	-	_	-	_	-	_	-
Return of capital	_	-	_	-	_	-	_	-
Management fee rebates								
Total distributions paid to securityholders								
Security transactions:								
Proceeds from securities issued	452	289	555	342	3,634	684	2,314	675
Reinvested distributions	_	-	_	-	_	-	_	-
Payments on redemption of securities	(103)	(112)	(2,467)	(1,717)	(2,789)	(1,319)	(6,267)	(6,392)
Total security transactions	349	177	(1,912)	(1,375)	845	(635)	(3,953)	(5,717)
Increase (decrease) in net assets attributable to securityholders	423	155	(1,558)	(1,677)	1,828	(991)	(2,156)	(6,948)
End of period	2,103	1,367	11,923	13,295	27,252	23,294	56,036	59,505
Increase (decrease) in fund securities (in thousands) (note 7):	Securi	ties	Securi	ties	Securi	ties	Securi	ties
Securities outstanding – beginning of period	164	134	488	603	2,218	2,392	4,573	5,829
Issued	43	31	21	14	313	67	181	60
Reinvested distributions	_	-	-	-	-	-	-	-
Redeemed	(10)	(12)	(90)	(69)	(243)	(131)	(492)	(562)
Securities outstanding – end of period	197	153	419	548	2,288	2,328	4,262	5,327

INTERIM UNAUDITED FINANCIAL STATEMENTS | September 30, 2024

STATEMENTS OF CASH FLOWS

for the periods ended September 30 (in \$ 000)

Cash flows from operating activities Net increase (decrease) in net assets attributable to securityholders from operations 99,953 (52,461) Adjustments for: Net realized loss (gain) on investments (114,451) 186,613 Change in net unrealized loss (gain) on investments (5,204) (155,683) Purchase of investments (355,646) (380,455) Proceeds from sale and maturity of investments 632,665 680,627 (Increase) decrease in accounts receivable and other assets 3,737 (274) Increase (decrease) in accounts payable and other liabilities (24) (12) Net cash provided by (used in) operating activities 261,030 278,355 Cash flows from financing activities (451,930) (338,471) Proceeds from securities issued 188,611 93,698 Payments on redemption of securities (451,930) (338,471) Distributions paid net of reinvestments (1,218) (1,415) Net cash provided by (used in) financing activities (264,537) (246,188) Net increase (decrease) in cash and cash equivalents at beginning of period 110,681 63,748		2024 \$	2023 \$
securityholders from operations 99,953 (52,461) Adjustments for: Net realized loss (gain) on investments (114,451) 186,613 Change in net unrealized loss (gain) on investments (5,204) (155,683) Purchase of investments (355,646) (380,455) Proceeds from sale and maturity of investments 632,665 680,627 (Increase) decrease in accounts receivable and other assets 3,737 (274) Increase (decrease) in accounts payable and other liabilities (24) (12) Net cash provided by (used in) operating activities 261,030 278,355 Cash flows from financing activities 8 188,611 93,698 Payments on redemption of securities (451,930) (338,471) Distributions paid net of reinvestments (1,218) (1,415) Net cash provided by (used in) financing activities (264,537) (246,188) Net increase (decrease) in cash and cash equivalents (3,507) 32,167 Cash and cash equivalents at beginning of period 110,681 63,748 Effect of exchange rate fluctuations on cash and cash equivalents (667) 1,776 <td>Cash flows from operating activities</td> <td></td> <td></td>	Cash flows from operating activities		
Net realized loss (gain) on investments (114,451) 186,613 Change in net unrealized loss (gain) on investments (5,204) (155,683) Purchase of investments (355,646) (380,455) Proceeds from sale and maturity of investments 632,665 680,627 (Increase) decrease in accounts receivable and other assets 3,737 (274) Increase (decrease) in accounts payable and other liabilities (24) (12) Net cash provided by (used in) operating activities 261,030 278,355 Cash flows from financing activities 188,611 93,698 Payments on redemption of securities (451,930) (338,471) Distributions paid net of reinvestments (1,218) (1,415) Net cash provided by (used in) financing activities (264,537) (246,188) Net increase (decrease) in cash and cash equivalents (3,507) 32,167 Cash and cash equivalents at beginning of period 110,681 63,748 Effect of exchange rate fluctuations on cash and cash equivalents (667) 1,776 Cash and cash equivalents at end of period 106,507 97,691 Cash equivalents	securityholders from operations	99,953	(52,461)
Change in net unrealized loss (gain) on investments (5,204) (155,683) Purchase of investments (355,646) (380,455) Proceeds from sale and maturity of investments 632,665 680,627 (Increase) decrease in accounts receivable and other assets 3,737 (274) Increase (decrease) in accounts payable and other liabilities (24) (12) Net cash provided by (used in) operating activities 261,030 278,355 Cash flows from financing activities 188,611 93,698 Payments on redemption of securities (451,930) (338,471) Distributions paid net of reinvestments (1,218) (1,415) Net cash provided by (used in) financing activities (264,537) (246,188) Net increase (decrease) in cash and cash equivalents (3,507) 32,167 Cash and cash equivalents at beginning of period 110,681 63,748 Effect of exchange rate fluctuations on cash and cash equivalents (667) 1,776 Cash and cash equivalents at end of period 106,507 97,691 Cash equivalents - - - Cash and cash equivalents at end of per	•	(114.451)	186.613
Purchase of investments (355,646) (380,455) Proceeds from sale and maturity of investments 632,665 680,627 (Increase) decrease in accounts receivable and other lassets 3,737 (274) Increase (decrease) in accounts payable and other liabilities (24) (12) Net cash provided by (used in) operating activities 261,030 278,355 Cash flows from financing activities 188,611 93,698 Proceeds from securities issued 188,611 93,698 Payments on redemption of securities (451,930) (338,471) Distributions paid net of reinvestments (1,218) (1,415) Net cash provided by (used in) financing activities (264,537) (246,188) Net increase (decrease) in cash and cash equivalents (3,507) 32,167 Cash and cash equivalents at beginning of period 110,681 63,748 Effect of exchange rate fluctuations on cash and cash equivalents (667) 1,776 Cash and cash equivalents at end of period 106,507 97,691 Cash equivalents - - - Cash and cash equivalents at end of period 1	<u> </u>		
Proceeds from sale and maturity of investments 632,665 680,627 (Increase) decrease in accounts receivable and other assets 3,737 (274) Increase (decrease) in accounts payable and other liabilities (24) (12) Net cash provided by (used in) operating activities 261,030 278,355 Cash flows from financing activities 188,611 93,698 Proceeds from securities issued 188,611 93,698 Payments on redemption of securities (451,930) (338,471) Distributions paid net of reinvestments (1,218) (1,415) Net cash provided by (used in) financing activities (264,537) (246,188) Net increase (decrease) in cash and cash equivalents (3,507) 32,167 Cash and cash equivalents at beginning of period 110,681 63,748 Effect of exchange rate fluctuations on cash and cash equivalents (667) 1,776 Cash and cash equivalents at end of period 106,507 97,691 Cash equivalents - - - Cash and cash equivalents at end of period 106,507 97,691 Cash and cash equivalents at end of period			
(Increase) decrease in accounts receivable and other lassets 3,737 (274) Increase (decrease) in accounts payable and other liabilities (24) (12) Net cash provided by (used in) operating activities 261,030 278,355 Cash flows from financing activities 188,611 93,698 Proceeds from securities issued 188,611 93,698 Payments on redemption of securities (451,930) (338,471) Distributions paid net of reinvestments (1,218) (1,415) Net cash provided by (used in) financing activities (264,537) (246,188) Net increase (decrease) in cash and cash equivalents (3,507) 32,167 Cash and cash equivalents at beginning of period 110,681 63,748 Effect of exchange rate fluctuations on cash and cash equivalents (667) 1,776 Cash and cash equivalents at end of period 106,507 97,691 Cash equivalents - - - Cash equivalents at end of period 106,507 97,691 Cash equivalents at end of period 106,507 97,691 Supplementary disclosures on cash flow from operating activities:	Proceeds from sale and maturity of investments		
Net cash provided by (used in) operating activities 261,030 278,355 Cash flows from financing activities 188,611 93,698 Proceeds from securities issued 188,611 93,698 Payments on redemption of securities (451,930) (338,471) Distributions paid net of reinvestments (1,218) (1,415) Net cash provided by (used in) financing activities (264,537) (246,188) Net increase (decrease) in cash and cash equivalents (3,507) 32,167 Cash and cash equivalents at beginning of period 110,681 63,748 Effect of exchange rate fluctuations on cash and cash equivalents (667) 1,776 Cash and cash equivalents at end of period 106,507 97,691 Cash equivalents — — Cash equivalents — — Cash and cash equivalents at end of period 106,507 97,691 Cash and cash equivalents at end of period 106,507 97,691 Supplementary disclosures on cash flow from operating activities: — — Dividends received 3,669 6,867 Foreign taxes paid		3,737	(274)
Cash flows from financing activities Proceeds from securities issued 188,611 93,698 Payments on redemption of securities (451,930) (338,471) Distributions paid net of reinvestments (1,218) (1,415) Net cash provided by (used in) financing activities (264,537) (246,188) Net increase (decrease) in cash and cash equivalents (3,507) 32,167 Cash and cash equivalents at beginning of period 110,681 63,748 Effect of exchange rate fluctuations on cash and cash equivalents (667) 1,776 Cash and cash equivalents at end of period 106,507 97,691 Cash and cash equivalents at end of period 106,507 97,691 Cash and cash equivalents at end of period 106,507 97,691 Supplementary disclosures on cash flow from operating activities: Dividends received 3,669 6,867 Foreign taxes paid 482 978 Interest received 2,577 2,108	Increase (decrease) in accounts payable and other liabilities	(24)	(12)
Proceeds from securities issued 188,611 93,698 Payments on redemption of securities (451,930) (338,471) Distributions paid net of reinvestments (1,218) (1,415) Net cash provided by (used in) financing activities (264,537) (246,188) Net increase (decrease) in cash and cash equivalents (3,507) 32,167 Cash and cash equivalents at beginning of period 110,681 63,748 Effect of exchange rate fluctuations on cash and cash equivalents (667) 1,776 Cash and cash equivalents at end of period 106,507 97,691 Cash equivalents — — Cash equivalents — — Cash equivalents at end of period 106,507 97,691 Cash and cash equivalents at end of period 106,507 97,691 Supplementary disclosures on cash flow from operating activities: — — Dividends received 3,669 6,867 Foreign taxes paid 482 978 Interest received 2,577 2,108	Net cash provided by (used in) operating activities	261,030	278,355
Proceeds from securities issued 188,611 93,698 Payments on redemption of securities (451,930) (338,471) Distributions paid net of reinvestments (1,218) (1,415) Net cash provided by (used in) financing activities (264,537) (246,188) Net increase (decrease) in cash and cash equivalents (3,507) 32,167 Cash and cash equivalents at beginning of period 110,681 63,748 Effect of exchange rate fluctuations on cash and cash equivalents (667) 1,776 Cash and cash equivalents at end of period 106,507 97,691 Cash equivalents — — Cash equivalents — — Cash equivalents at end of period 106,507 97,691 Cash and cash equivalents at end of period 106,507 97,691 Supplementary disclosures on cash flow from operating activities: — — Dividends received 3,669 6,867 Foreign taxes paid 482 978 Interest received 2,577 2,108			
Payments on redemption of securities (451,930) (338,471) Distributions paid net of reinvestments (1,218) (1,415) Net cash provided by (used in) financing activities (264,537) (246,188) Net increase (decrease) in cash and cash equivalents (3,507) 32,167 Cash and cash equivalents at beginning of period 110,681 63,748 Effect of exchange rate fluctuations on cash and cash equivalents (667) 1,776 Cash and cash equivalents at end of period 106,507 97,691 Cash equivalents — — Cash equivalents — — Cash and cash equivalents at end of period 106,507 97,691 Supplementary disclosures on cash flow from operating activities: — — Dividends received 3,669 6,867 Foreign taxes paid 482 978 Interest received 2,577 2,108	Cash flows from financing activities		
Distributions paid net of reinvestments (1,218) (1,415) Net cash provided by (used in) financing activities (264,537) (246,188) Net increase (decrease) in cash and cash equivalents (3,507) 32,167 Cash and cash equivalents at beginning of period 110,681 63,748 Effect of exchange rate fluctuations on cash and cash equivalents (667) 1,776 Cash and cash equivalents at end of period 106,507 97,691 Cash equivalents — — Cash equivalents — — Cash and cash equivalents at end of period 106,507 97,691 Cash and cash equivalents at end of period 106,507 97,691 Supplementary disclosures on cash flow from operating activities: 3,669 6,867 Dividends received 3,669 6,867 Foreign taxes paid 482 978 Interest received 2,577 2,108	Proceeds from securities issued	188,611	93,698
Net cash provided by (used in) financing activities (264,537) (246,188) Net increase (decrease) in cash and cash equivalents (3,507) 32,167 Cash and cash equivalents at beginning of period 110,681 63,748 Effect of exchange rate fluctuations on cash and cash equivalents (667) 1,776 Cash and cash equivalents at end of period 106,507 97,691 Cash equivalents – – Cash equivalents – – Cash and cash equivalents at end of period 106,507 97,691 Supplementary disclosures on cash flow from operating activities: 3,669 6,867 Dividends received 3,669 6,867 Foreign taxes paid 482 978 Interest received 2,577 2,108	Payments on redemption of securities	(451,930)	(338,471)
Net increase (decrease) in cash and cash equivalents (3,507) 32,167 Cash and cash equivalents at beginning of period 110,681 63,748 Effect of exchange rate fluctuations on cash and cash equivalents (667) 1,776 Cash and cash equivalents at end of period 106,507 97,691 Cash equivalents – – Cash equivalents – – Cash and cash equivalents at end of period 106,507 97,691 Supplementary disclosures on cash flow from operating activities: – – Dividends received 3,669 6,867 Foreign taxes paid 482 978 Interest received 2,577 2,108	Distributions paid net of reinvestments	(1,218)	(1,415)
Cash and cash equivalents at beginning of period 110,681 63,748 Effect of exchange rate fluctuations on cash and cash equivalents (667) 1,776 Cash and cash equivalents at end of period 106,507 97,691 Cash equivalents - - Cash equivalents - - Cash and cash equivalents at end of period 106,507 97,691 Supplementary disclosures on cash flow from operating activities: 3,669 6,867 Dividends received 3,669 6,867 Foreign taxes paid 482 978 Interest received 2,577 2,108	Net cash provided by (used in) financing activities	(264,537)	(246,188)
Cash and cash equivalents at beginning of period 110,681 63,748 Effect of exchange rate fluctuations on cash and cash equivalents (667) 1,776 Cash and cash equivalents at end of period 106,507 97,691 Cash equivalents - - Cash equivalents - - Cash and cash equivalents at end of period 106,507 97,691 Supplementary disclosures on cash flow from operating activities: 3,669 6,867 Dividends received 3,669 6,867 Foreign taxes paid 482 978 Interest received 2,577 2,108			
Effect of exchange rate fluctuations on cash and cash equivalents (667) 1,776 Cash and cash equivalents at end of period 106,507 97,691 Cash equivalents - - Cash equivalents - - Cash and cash equivalents at end of period 106,507 97,691 Supplementary disclosures on cash flow from operating activities: 3,669 6,867 Dividends received 3,669 6,867 Foreign taxes paid 482 978 Interest received 2,577 2,108	Net increase (decrease) in cash and cash equivalents	(3,507)	
equivalents (667) 1,776 Cash and cash equivalents at end of period 106,507 97,691 Cash 106,507 97,691 Cash equivalents - - Cash and cash equivalents at end of period 106,507 97,691 Supplementary disclosures on cash flow from operating activities: Dividends received 3,669 6,867 Foreign taxes paid 482 978 Interest received 2,577 2,108	, , ,	110,681	63,748
Cash and cash equivalents at end of period 106,507 97,691 Cash 106,507 97,691 Cash equivalents — — Cash and cash equivalents at end of period 106,507 97,691 Supplementary disclosures on cash flow from operating activities: Supplementary disclosures on cash flow from operating activities: 3,669 6,867 Foreign taxes paid 482 978 978 1100 11	•		
Cash 106,507 97,691 Cash equivalents — — Cash and cash equivalents at end of period 106,507 97,691 Supplementary disclosures on cash flow from operating activities: Dividends received 3,669 6,867 Foreign taxes paid 482 978 Interest received 2,577 2,108			
Cash equivalents - - Cash and cash equivalents at end of period 106,507 97,691 Supplementary disclosures on cash flow from operating activities: Dividends received 3,669 6,867 Foreign taxes paid 482 978 Interest received 2,577 2,108	Cash and cash equivalents at end of period	106,507	97,691
Cash and cash equivalents at end of period106,50797,691Supplementary disclosures on cash flow from operating activities:Dividends received3,6696,867Foreign taxes paid482978Interest received2,5772,108		106,507	97,691
Supplementary disclosures on cash flow from operating activities: Dividends received 3,669 6,867 Foreign taxes paid 482 978 Interest received 2,577 2,108		106.507	97.691
activities: Dividends received 3,669 6,867 Foreign taxes paid 482 978 Interest received 2,577 2,108	outh and saon squivalents at one of period	100,007	07,001
Foreign taxes paid 482 978 Interest received 2,577 2,108			
Interest received 2,577 2,108	Dividends received	3,669	6,867
Interest received 2,577 2,108	Foreign taxes paid	482	978
	3 1	2,577	2,108
	Interest paid	3	1

INTERIM UNAUDITED FINANCIAL STATEMENTS | September 30, 2024

SCHEDULE OF INVESTMENTS

as at September 30, 2024

Investment Name	Country	Sector	Par Value/ Number of Shares/Units	Average Cost (\$ 000)	Fai Value (\$ 000
EQUITIES					
Akamai Technologies Inc.	United States	Information Technology	1,050,372	155,908	143,397
Amedisys Inc.	United States	Health Care	317,157	61,735	41,39
Axonics Modulation Technologies Inc.	United States	Health Care	912,097	71,338	85,85
Bio-Techne Corp.	United States	Health Care	1,251,758	142,682	135,30
Charles River Laboratories International Inc.	United States	Health Care	417,912	149,506	111,32
Cirrus Logic Inc.	United States	Information Technology	717,729	74,048	120,56
Cognex Corp.	United States	Information Technology	858,119	47,432	47,00
CommVault Systems Inc.	United States	Information Technology	484,362	44,282	100,77
CoStar Group Inc.	United States	Real Estate	1.253.719	110,197	127,90
Dolby Laboratories Inc. Class A	United States	Information Technology	444,594	53,391	46.01
DoubleVerify Holdings Inc.	United States	Information Technology	3,341,860	95,316	76.10
Exact Sciences Corp.	United States	Health Care	641,141	42,658	59,06
ExlService Holdings Inc.	United States	Industrials	3,182,117	101,919	164,17
Generac Holdings Inc.	United States	Industrials	200,267	32,865	43,03
Grocery Outlet Holding Corp.	United States	Consumer Staples	3,628,661	134,776	86,12
Healthcare Services Group Inc.	United States	Industrials	3,031,046	98,671	45,78
HealthEquity Inc.	United States	Health Care	1,081,348	96,029	119,69
Inari Medical Inc.	United States	Health Care	622,189	36,407	34,70
iRhythm Technologies Inc.	United States	Health Care	1,043,142	87,014	104,73
JFrog Ltd.	Israel	Information Technology	754,800	27,227	29,64
Kennedy-Wilson Holdings Inc.	United States	Real Estate	3,307,653	80,290	49,42
Keysight Technologies Inc.	United States	Information Technology	475.527	98,556	102,20
LivePerson Inc.	United States	Information Technology	962,939	76,494	1,66
Maravai LifeSciences Holdings Inc.	United States	Health Care	4,573,360	74,558	51,39
Markel Corp.	United States	Financials	16,849	25,348	35,74
MAXIMUS Inc.	United States	Industrials	1,342,210	148,993	169,09
Neogen Corp.	United States	Health Care	5,440,195	117,580	123,67
Parsons Corp.	United States	Industrials	749,641	36,025	105,10
Rackspace Technology Inc.	United States	Information Technology	4,217,191	88,978	13,97
Tenable Holdings Inc.	United States	Information Technology	2,123,349	115,195	116,35
TransMedics Group Inc.	United States	Health Care	348,576	24,954	74,01
Verra Mobility Corp.	United States	Industrials	3,820,617	75,375	143,69
Wabtec Corp.	United States	Industrials Industrials	379,764	40,200	93,35
Total equities	United States	illuustilais	3/3,/04	2,665,947	2,802,27
iotai equities			_	2,000,947	2,002,27
Transaction costs				(2,756)	
Total investments			_	2,663,191	2,802,27
Cash and cash equivalents					106,50
Other assets less liabilities					(9
Net assets attributable to securityholders				_	2,908,68

INTERIM UNAUDITED FINANCIAL STATEMENTS | September 30, 2024

SUMMARY OF INVESTMENT PORTFOLIO

SEPTEMBER 30, 2024		MARCH 31, 2024				
PORTFOLIO ALLOCATION	% OF NAV	PORTFOLIO ALLOCATION	% OF NAV			
Equities 96.3 Equiti		Equities Cash and cash equivalents	96.4 3.6			
REGIONAL ALLOCATION	% OF NAV	REGIONAL ALLOCATION	% OF NAV			
United States Cash and cash equivalents Israel	95.3 3.7 1.0	United States Cash and cash equivalents	96.4 3.6			
SECTOR ALLOCATION	% OF NAV	SECTOR ALLOCATION	% OF NAV			
Health care	32.3	Health care	27.8			
Information technology	27.4	Industrials	27.1			
Industrials	26.3	Information technology	26.6			
Real estate	6.1	Real estate	5.2			
Cash and cash equivalents	3.7	Consumer staples	4.6			
Consumer staples	3.0	Financials	4.1			
Financials	1.2	Cash and cash equivalents	3.6			
		Consumer discretionary	1.0			

INTERIM UNAUDITED FINANCIAL STATEMENTS | September 30, 2024

NOTES TO FINANCIAL STATEMENTS

1. Fiscal Periods and General Information

The information provided in these financial statements and notes thereto is for the six-month periods ended or as at September 30, 2024 and 2023, except for the comparative information presented in the Statements of Financial Position and notes thereto, which is as at March 31, 2024. In the year a Fund or series is established or reinstated, 'period' represents the period from inception or reinstatement. Where a series of a Fund was terminated during either period, the information for the series is provided up to close of business on the termination date. Refer to Note 10 (a) for the formation date of the Fund and the inception date of each series

The Fund is organized as an open-ended mutual fund trust established under the laws of the Province of Ontario pursuant to a Declaration of Trust as amended and restated from time to time. The address of the Fund's registered office is 180 Queen Street West, Toronto, Ontario, Canada. The Fund is authorized to issue an unlimited number of units (referred to as "security" or "securities") of multiple series. Series of the Fund are available for sale under Simplified Prospectus or exempt distribution options.

Mackenzie Financial Corporation ("Mackenzie") is the manager of the Fund and is wholly owned by IGM Financial Inc., a subsidiary of Power Corporation of Canada. Canada Life Investment Management Ltd. ("CLIML") is wholly owned by The Canada Life Assurance Company ("Canada Life"), a subsidiary of Power Corporation of Canada. Investments in companies within the Power Group of companies held by the Fund are identified in the Schedule of Investments.

2. Basis of Preparation and Presentation

These unaudited interim financial statements ("financial statements") have been prepared in accordance with IFRS Accounting Standards ("IFRS"), including international Accounting Standard ("IAS") 34, *Interim Financial Reporting*, as issued by the International Accounting Standards Board ("IASB"). These financial statements were prepared using the same accounting policies, critical accounting judgements and estimates as applied in the Fund's most recent audited annual financial statements for the year ended March 31, 2024. A summary of the Fund's material accounting policies under IFRS is presented in Note 3.

These financial statements are presented in Canadian dollars, which is the Fund's functional and presentation currency, and rounded to the nearest thousand unless otherwise indicated. These financial statements are prepared on a going concern basis using the historical cost basis, except for financial instruments that have been measured at fair value.

These financial statements were authorized for issue by the Board of Directors of Mackenzie Financial Corporation on November 12, 2024.

3. Material Accounting Policies

(a) Financial instruments

Financial instruments include financial assets and liabilities such as debt and equity securities, investment funds and derivatives. The Fund classifies and measures financial instruments in accordance with IFRS 9, *Financial Instruments* ("IFRS 9"). Upon initial recognition, financial instruments are classified as fair value through profit or loss ("FVTPL"). All financial instruments are recognized in the Statement of Financial Position when the Fund becomes a party to the contractual requirements of the instrument. Financial assets are derecognized when the right to receive cash flows from the instrument has expired or the Fund has transferred substantially all risks and rewards of ownership. Financial liabilities are derecognized when the obligation is discharged, cancelled or expires. Investment purchase and sale transactions are recorded as of the trade date.

Financial instruments are subsequently measured at FVTPL with changes in fair value recognized in the Statement of Comprehensive Income — Other changes in fair value of investments and other net assets — Net unrealized gain (loss).

The cost of investments is determined on a weighted average cost basis.

Realized and unrealized gains and losses on investments are calculated based on the weighted average cost of investments and exclude commissions and other portfolio transaction costs, which are separately reported in the Statement of Comprehensive Income — Commissions and other portfolio transaction costs.

Gains and losses arising from changes in the fair value of the investments are included in the Statement of Comprehensive Income for the period in which they arise.

The Fund accounts for its holdings in unlisted open-ended investment funds, private funds ("Underlying Funds") and Exchange-Traded Funds ("ETFs"), if any, at FVTPL. For private funds, the Manager will rely on the valuations provided by the managers of the private funds, which represents the Fund's proportionate share of the net assets of these private funds. The Fund's investment in Underlying Funds and ETFs, if any, is presented in the Schedule of Investments at fair value which represents the Fund's maximum exposure on these investments.

The Fund's redeemable securities contain multiple dissimilar contractual obligations and entitle securityholders to the right to redeem their interest in the Fund for cash equal to their proportionate share of the net asset value of the Fund and therefore meet the criteria for classification as financial liabilities under IAS 32 *Financial Instruments: Presentation.* The Fund's obligation for net assets attributable to securityholders is presented at the redemption amount.

IAS 7, Statement of Cash Flows, requires disclosures related to changes in liabilities and assets, such as the securities of the Fund, arising from financing activities. Changes in securities of the Fund, including both changes from cash flows and non-cash changes, are included in the Statement of Changes in Financial Position. Any changes in the securities not settled in cash as at the end of the period are presented as either Accounts receivable for securities issued or Accounts payable for securities redeemed in the Statement of Financial Position. These accounts receivable and accounts payable amounts typically settle shortly after period-end.

(b) Fair value measurement

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

INTERIM UNAUDITED FINANCIAL STATEMENTS | September 30, 2024

NOTES TO FINANCIAL STATEMENTS

3. Material Accounting Policies (cont'd)

(b) Fair value measurement (cont'd)

Investments listed on a public securities exchange or traded on an over-the-counter market, including ETFs, are valued on the basis of the last traded market price or closing price recorded by the security exchange on which the security is principally traded, where this price falls within the quoted bid-ask spread for the investment. In circumstances where this price is not within the bid-ask spread, Mackenzie determines the point within the bid-ask spread that is most representative of fair value based on the specific facts and circumstances. Mutual fund securities of an underlying fund are valued on a business day at the price calculated by the manager of such underlying fund in accordance with the constating documents of such underlying fund. Unlisted or non-exchange traded investments, or investments where a last sale or close price is unavailable or investments for which market quotations are, in Mackenzie's opinion, inaccurate, unreliable, or not reflective of all available material information, are valued at their fair value as determined by Mackenzie using appropriate and accepted industry valuation techniques including valuation models. The fair value determined using valuation models requires the use of inputs and assumptions based on observable market data including volatility and other applicable rates or prices. In limited circumstances, the fair value may be determined using valuation techniques that are not supported by observable market data.

Cash and cash equivalents which includes cash on deposit with financial institutions and short-term investments that are readily convertible to cash, are subject to an insignificant risk of changes in value, and are used by the Fund in the management of short-term commitments. Cash and cash equivalents and short-term investments are reported at fair value which closely approximates their amortized cost due to their nature of being highly liquid and having short terms to maturity. Bank overdraft positions are presented under current liabilities as bank indebtedness in the Statement of Financial Position. Short-term investments that are not considered cash equivalents are separately disclosed in the Schedule of Investments.

The Fund may use derivatives (such as written options, futures, forward contracts, swaps or customized derivatives) to hedge against losses caused by changes in securities prices, interest rates or exchange rates. The Fund may also use derivatives for non-hedging purposes in order to invest indirectly in securities or financial markets, to gain exposure to other currencies, to seek to generate additional income, and/or for any other purpose considered appropriate by the Fund's portfolio manager(s), provided that the use of the derivative is consistent with the Fund's investment objectives. Any use of derivatives will comply with Canadian mutual fund laws, subject to the regulatory exemptions granted to the Fund, as applicable.

Valuations of derivative instruments are carried out daily, using normal exchange reporting sources for exchange-traded derivatives and specific broker enquiry for over-the-counter derivatives.

The value of forward contracts is the gain or loss that would be realized if, on the valuation date, the positions were to be closed out. The change in value of forward contracts is included in the Statement of Comprehensive Income — Other changes in fair value of investments and other net assets — Net unrealized gain (loss).

The daily fluctuation of futures contracts or swaps, along with daily cash settlements made by the Fund, where applicable, are equal to the change in unrealized gains or losses that are best determined at the settlement price. These unrealized gains or losses are recorded and reported as such until the Fund closes out the contract or the contract expires. Margin paid or deposited in respect of futures contracts or swaps is reflected as a receivable in the Statement of Financial Position — Margin on derivatives. Any change in the variation margin requirement is settled daily.

Premiums paid for purchasing an option are recorded in the Statement of Financial Position – Investments at fair value.

Premiums received from writing options are included in the Statement of Financial Position as a liability and subsequently adjusted daily to fair value. If a written option expires unexercised, the premium received is recognized as a realized gain. If a written call option is exercised, the difference between the proceeds of the sale plus the value of the premium, and the cost of the security is recognized as a realized gain or loss. If a written put option is exercised, the cost of the security acquired is the exercise price of the option less the premium received.

Refer to the Schedule of Derivative Instruments and Schedule of Options Purchased/Written, as applicable, included in the Schedule of Investments for a listing of derivative and options positions as at September 30, 2024.

The Fund categorizes the fair value of its assets and liabilities into three categories, which are differentiated based on the observable nature of the inputs and extent of estimation required.

Level 1- Unadjusted quoted prices in active markets for identical assets or liabilities;

Level 2 – Inputs other than quoted prices that are observable for the asset or liability either directly or indirectly. Examples of Level 2 valuations include quoted prices for similar securities, quoted prices on inactive markets and from recognized investment dealers, and the application of factors derived from observable data to non-North American quoted prices in order to estimate the impact of differences in market closing times.

Financial instruments classified as Level 2 investments are valued based on the prices provided by an independent reputable pricing services company who prices the securities based on recent transactions and quotes received from market participants and through incorporating observable market data and using standard market convention practices. Short-term investments classified as Level 2 investments are valued based on amortized cost plus accrued interest which closely approximates fair value.

The estimated fair values for these securities may be different from the values that would have been used had a ready market for the investment existed; and Level 3 – Inputs that are not based on observable market data.

The inputs are considered observable if they are developed using market data, such as publicly available information about actual events or transactions, and that reflect the assumption that market participants would use when pricing the asset or liability.

See Note 10 for the fair value classifications of the Fund.

(c) Income recognition

Interest income for distribution purposes represents the coupon interest received by the Fund which is accounted for on an accrual basis. The Fund does not amortize premiums paid or discounts received on the purchase of fixed income securities except for zero coupon bonds, which are amortized on a straight-line basis. Dividends are accrued as of the ex-dividend date. Unrealized gains or losses on investments, realized gains or losses on the sale of investments, including foreign exchange gains or losses on such investments, are calculated on a weighted average cost basis. Distributions received from an underlying fund are included in interest income, dividend income, realized gains (losses) on sale of investments or fee rebate income, as appropriate, on the ex-dividend or distribution date.

Income, realized gains (losses) and unrealized gains (losses) are allocated daily among the series on a pro-rata basis.

INTERIM UNAUDITED FINANCIAL STATEMENTS | September 30, 2024

NOTES TO FINANCIAL STATEMENTS

3. Material Accounting Policies (cont'd)

(d) Commissions and other portfolio transaction costs

Commissions and other portfolio transaction costs are costs incurred to acquire, issue or dispose of financial assets or liabilities. They include fees and commissions paid to agents, exchanges, brokers, dealers and other intermediaries. The total brokerage commissions incurred by the Fund in connection with portfolio transactions for the periods, together with other transaction charges, is disclosed in the Statements of Comprehensive Income. Brokerage business is allocated to brokers based on the best net result for the Fund. Subject to this criteria, commissions may be paid to brokerage firms which provide (or pay for) certain services, other than order execution, which may include investment research, analysis and reports, and databases or software in support of these services. Where applicable and ascertainable, the value of these services generated during the periods is disclosed in Note 10. The value of certain proprietary services provided by brokers cannot be reasonably estimated.

(e) Securities lending, repurchase and reverse repurchase transactions

The Fund is permitted to enter into securities lending, repurchase and reverse repurchase transactions as set out in the Fund's Simplified Prospectus. These transactions involve the temporary exchange of securities for collateral with a commitment to redeliver the same securities on a future date.

Income is earned from these transactions in the form of fees paid by the counterparty and, in certain circumstances, interest paid on cash or securities held as collateral. Income earned from these transactions is included in the Statement of Comprehensive Income and recognized when earned. Securities lending transactions are administered by The Bank of New York Mellon (the "Securities Lending Agent"). The value of cash or securities held as collateral must be at least 102% of the fair value of the securities loaned, sold or purchased.

Note 10 summarizes the details of securities loaned and collateral received as at the end of period, as well as a reconciliation of securities lending income during the period, if applicable. Collateral received is comprised of debt obligations of the Government of Canada and other countries, Canadian provincial and municipal governments, and financial institutions.

(f) Offsetting

Financial assets and liabilities are offset and the net amount reported in the Statement of Financial Position only when there is a legally enforceable right to offset the recognized amounts and there is an intention to settle on a net basis, or to realize the asset and settle the liability simultaneously. In the normal course of business, the Fund enters into various master netting agreements or similar agreements that do not meet the criteria for offsetting in the Statement of Financial Position but still allow for the related amounts to be set off in certain circumstances, such as bankruptcy or termination of the contracts. Note 10 summarizes the details of such offsetting, if applicable, subject to master netting arrangements or other similar agreements and the net impact to the Statements of Financial Position if all such rights were exercised.

Income and expenses are not offset in the Statement of Comprehensive Income unless required or permitted to by an accounting standard, as specifically disclosed in the IFRS policies of the Fund.

(g) Currency

The functional and presentation currency of the Fund is Canadian dollars. Foreign currency purchases and sales of investments and foreign currency dividend and interest income and expenses are translated to Canadian dollars at the rate of exchange prevailing at the time of the transactions.

Foreign exchange gains (losses) on purchases and sales of foreign currencies are included in the Statement of Comprehensive Income – Other changes in fair value of investments and other net assets – Net realized gain (loss).

The fair value of investments and other assets and liabilities, denominated in foreign currencies, are translated to Canadian dollars at the rate of exchange prevailing on each business day.

(h) Net assets attributable to securityholders per security

Net assets attributable to securityholders per security is computed by dividing the net assets attributable to securityholders of a series of securities on a business day by the total number of securities of the series outstanding on that day.

(i) Net asset value per security

The daily Net Asset Value ("NAV") of an investment fund may be calculated without reference to IFRS as per the Canadian Securities Administrators' ("CSA") regulations. The difference between NAV and Net assets attributable to securityholders (as reported in the financial statements), if any, is mainly due to differences in fair value of investments and other financial assets and liabilities and is disclosed in Note 10, if applicable.

(j) Increase (decrease) in net assets attributable to securityholders from operations per security

Increase (decrease) in net assets attributable to securityholders from operations per security in the Statement of Comprehensive Income represents the increase (decrease) in net assets attributable to securityholders from operations for the period, divided by the weighted average number of securities outstanding during the period.

(k) Mergers

In a fund merger, the Fund acquires all of the assets and assumes all of the liabilities of the terminating fund at fair value in exchange for securities of the Fund on the effective date of the merger.

(I) Future accounting changes

The Fund has determined there are no material implications to the Fund's financial statements arising from IFRS issued but not yet effective.

INTERIM UNAUDITED FINANCIAL STATEMENTS | September 30, 2024

NOTES TO FINANCIAL STATEMENTS

4. Critical Accounting Estimates and Judgments

The preparation of these financial statements requires management to make estimates and assumptions that primarily affect the valuation of investments. Estimates and assumptions are reviewed on an ongoing basis. Actual results may differ from these estimates.

The following discusses the most significant accounting judgments and estimates made in preparing the financial statements:

Use of Estimates

Fair value of securities not quoted in an active market

The Fund may hold financial instruments that are not quoted in active markets and are valued using valuation techniques that make use of observable data, to the extent practicable. Various valuation techniques are utilized, depending on a number of factors, including comparison with similar instruments for which observable market prices exist and recent arm's length market transactions. Key inputs and assumptions used are company specific and may include estimated discount rates and expected price volatilities. Changes in key inputs, could affect the reported fair value of these financial instruments held by the Fund.

Use of Judgments

Classification and measurement of investments

In classifying and measuring financial instruments held by the Fund, Mackenzie is required to make significant judgments in order to determine the most appropriate classification in accordance with IFRS 9. Mackenzie has assessed the Fund's business model, the manner in which all financial instruments are managed and performance evaluated as a group on a fair value basis, and concluded that FVTPL in accordance with IFRS 9 provides the most appropriate measurement and presentation of the Fund's financial instruments.

Functional currency

The Fund's functional and presentation currency is the Canadian dollar, which is the currency considered to best represent the economic effects of the Fund's underlying transactions, events and conditions taking into consideration the manner in which securities are issued and redeemed and how returns and performance by the Fund are measured.

Interest in unconsolidated structured entities

In determining whether an Underlying Fund or an ETF in which the Fund invests, but that it does not consolidate, meets the definition of a structured entity, Mackenzie is required to make significant judgments about whether these underlying funds have the typical characteristics of a structured entity. These Underlying Funds do meet the definition of a structured entity because:

- I. The voting rights in the Underlying Funds are not dominant factors in deciding who controls them;
- II. the activities of the Underlying Funds are restricted by their offering documents; and
- III. the Underlying Funds have narrow and well-defined investment objectives to provide investment opportunities for investors while passing on the associated risks and rewards.

As a result, such investments are accounted for at FVTPL. Note 10 summarizes the details of the Fund's interest in these Underlying Funds, if applicable.

5. Income Taxes

The Fund qualifies as a mutual fund trust under the provisions of the Income Tax Act (Canada) and, accordingly, is subject to tax on its income including net realized capital gains in the taxation year, which is not paid or payable to its securityholders as at the end of the taxation year. The Fund maintains a December year-end for tax purposes. The Fund may be subject to withholding taxes on foreign income. In general, the Fund treats withholding tax as a charge against income for tax purposes. The Fund will distribute sufficient amounts from net income for tax purposes, as required, so that the Fund will not pay income taxes other than refundable tax on capital gains. if applicable.

Losses of the Fund cannot be allocated to investors and are retained in the Fund for use in future years. Non-capital losses may be carried forward up to 20 years to reduce taxable income and realized capital gains of future years. Capital losses may be carried forward indefinitely to reduce future realized capital gains. Refer to Note 10 for the Fund's loss carryforwards.

6. Management Fees and Operating Expenses

Mackenzie is paid a management fee for managing the investment portfolio, providing investment analysis and recommendations, making investment decisions, making brokerage arrangements relating to the purchase and sale of the investment portfolio and making arrangements with registered dealers for the purchase and sale of securities of the Fund by investors. The management fee is calculated on each series of securities of the Fund as a fixed annual percentage of the daily net asset value of the series.

Each series of the Fund, except B-Series, is charged a fixed rate annual administration fee ("Administration Fee") and in return, Mackenzie bears all of the operating expenses of the Fund, other than certain specified fund costs. The Administration Fee is calculated on each series of securities of the Fund as a fixed annual percentage of the daily net asset value of the series.

Other fund costs include taxes (including, but not limited to GST/HST and income tax), interest and borrowing costs, all fees and expenses of the Mackenzie Funds' Independent Review Committee ("IRC"), costs of complying with the regulatory requirement to produce Fund Facts, fees paid to external service providers associated with tax reclaims, refunds or the preparation of foreign tax reports on behalf of the Funds, new fees related to external services that were not commonly charged in the Canadian mutual fund industry and introduced after the date of the most recently filed simplified prospectus, and the costs of complying with any new regulatory requirements, including, without limitation, any new fees introduced after the date of the most recently filed simplified prospectus.

All expenses relating to the operation of the Fund attributable to B-Series securities will be charged to that particular series. Operating expenses include legal, audit, transfer agent, custodian, administration and trustee services, cost of financial reporting and Simplified Prospectus printing, regulatory filing fees and other miscellaneous expenses specifically attributable to the B-Series securities and any applicable taxes.

INTERIM UNAUDITED FINANCIAL STATEMENTS | September 30, 2024

NOTES TO FINANCIAL STATEMENTS

6. Management Fees and Operating Expenses (cont'd)

Mackenzie may waive or absorb management fees and/or Administration Fees at its discretion and stop waiving or absorbing such fees at any time without notice. Refer to Note 10 for the management fee and Administration Fee rates charged to each series of securities.

7. Fund's Capital

The capital of the Fund, which is comprised of the net assets attributable to securityholders, is divided into different series with each series having an unlimited number of securities. The securities outstanding for the Fund as at September 30, 2024 and 2023 and securities issued, reinvested and redeemed for the periods are presented in the Statement of Changes in Financial Position. Mackenzie manages the capital of the Fund in accordance with the investment objectives as discussed in Note 10.

8. Financial Instruments Risk

i. Risk exposure and management

The Fund's investment activities expose it to a variety of financial risks, as defined in IFRS 7, *Financial Instruments: Disclosures* ("IFRS 7"). The Fund's exposure to financial risks is concentrated in its investments, which are presented in the Schedule of Investments, as at September 30, 2024, grouped by asset type, with geographic and sector information.

Mackenzie seeks to minimize potential adverse effects of financial risks on the Fund's performance by employing professional, experienced portfolio advisors, by monitoring the Fund's positions and market events daily, by diversifying the investment portfolio within the constraints of the Fund's investment objectives, and where applicable, by using derivatives to hedge certain risk exposures. To assist in managing risks, Mackenzie also maintains a governance structure that oversees the Fund's investment activities and monitors compliance with the Fund's stated investment strategy, internal guidelines, and securities regulations.

ii. Liquidity risk

Liquidity risk arises when the Fund encounters difficulty in meeting its financial obligations as they become due. The Fund is exposed to liquidity risk due to potential daily cash redemptions of redeemable securities. In order to monitor the liquidity of its assets, the Fund utilizes a liquidity risk management program that calculates the number of days to convert the investments held by the Fund into cash using a multi-day liquidation approach. This liquidity risk analysis assesses the Fund's liquidity against predetermined minimum liquidity percentages established for different time periods and is monitored quarterly. In addition, the Fund has the ability to borrow up to 5% of its net assets for the purposes of funding redemptions.

In order to comply with securities regulations, the Fund must maintain at least 85% of its assets in liquid investments (i.e., investments that can be readily sold).

iii. Currency risk

Currency risk is the risk that financial instruments which are denominated or exchanged in a currency other than the Canadian dollar, which is the Fund's functional currency, will fluctuate due to changes in exchange rates. Generally, foreign denominated investments increase in value when the value of the Canadian dollar (relative to foreign currencies) falls. Conversely, when the value of the Canadian dollar rises relative to foreign currencies, the values of foreign denominated investments fall.

Note 10 indicates the foreign currencies, if applicable, to which the Fund had significant exposure, including both monetary and non-monetary financial instruments, and illustrates the potential impact, in Canadian dollar terms, to the Fund's net assets had the Canadian dollar strengthened or weakened by 5% relative to all foreign currencies, all other variables held constant. In practice, the actual trading results may differ and the difference could be material.

The Fund's sensitivity to currency risk illustrated in Note 10 includes potential indirect impacts from underlying funds and ETFs in which the Fund invests, and/or derivative contracts including forward currency contracts. Other financial assets and liabilities (including dividends and interest receivable, and receivables/payables for investments sold/purchased) that are denominated in foreign currencies do not expose the Fund to significant currency risk.

iv. Interest rate risk

Interest rate risk arises on interest-bearing financial instruments. The Fund is exposed to the risk that the value of interest-bearing financial instruments will fluctuate due to changes in the prevailing levels of market interest rates. Generally, these securities increase in value when interest rates fall and decrease in value when interest rates rise.

If significant, Note 10 summarizes the Fund's interest-bearing financial instruments by remaining term to maturity and illustrates the potential impact to the Fund's net assets had prevailing interest rates increased or decreased by 1%, assuming a parallel shift in the yield curve, all other variables held constant. The Fund's sensitivity to interest rate changes was estimated using weighted average duration. In practice, the actual trading results may differ and the difference could be material.

The Fund's sensitivity to interest rate risk illustrated in Note 10 includes potential indirect impacts from underlying funds and ETFs in which the Fund invests, and/or derivative contracts. Cash and cash equivalents and other money market instruments are short term in nature and are not generally subject to significant amounts of interest rate risk.

v. Other price risk

Other price risk is the risk that the value of financial instruments will fluctuate as a result of changes in market prices (other than those arising from interest rate risk or currency risk), whether caused by factors specific to an individual investment, its issuer, or all factors affecting all instruments traded in a market or market segment. All investments present a risk of loss of capital. This risk is managed through a careful selection of investments and other financial instruments within the parameters of the investment strategies. Except for certain derivative contracts, the maximum risk resulting from financial instruments is equivalent to their fair value. The maximum risk of loss on certain derivative contracts such as forwards, swaps, and futures contracts is equal to their notional values. In the case of written call (put) options and short futures contracts, the loss to the Fund continues to increase, theoretically without limit, as the fair value of the underlying interest increases (decreases). However, these instruments are generally used within the overall investment management process to manage the risk from the underlying investments and do not typically increase the overall risk of loss to the Fund. This risk is mitigated by ensuring that the Fund holds a combination of the underlying interest, cash cover and/or margin that is equal to or greater than the value of the derivative contract.

INTERIM UNAUDITED FINANCIAL STATEMENTS | September 30, 2024

NOTES TO FINANCIAL STATEMENTS

8. Financial Instruments Risk (cont'd)

v. Other price risk (cont'd)

Other price risk typically arises from exposure to equity and commodity securities. If significant, Note 10 illustrates the potential increase or decrease in the Fund's net assets, had the prices on the respective exchanges for these securities increased or decreased by 10%, all other variables held constant. In practice, the actual trading results may differ and the difference could be material.

The Fund's sensitivity to other price risk illustrated in Note 10 includes potential indirect impacts from underlying funds and ETFs in which the Fund invests, and/or derivative contracts.

vi. Credit risk

Credit risk is the risk that a counterparty to a financial instrument will fail to discharge an obligation or commitment that it has entered into with the Fund. Note 10 summarizes the Fund's exposure, if applicable and significant, to credit risk.

If presented, credit ratings and rating categories are based on ratings issued by a designated rating organization. Indirect exposure to credit risk may arise from fixed-income securities, such as bonds, held by underlying funds and ETFs, if any. The fair value of debt securities includes consideration of the creditworthiness of the debt issuer.

To minimize the possibility of settlement default, securities are exchanged for payment simultaneously, where market practices permit, through the facilities of a central depository and/or clearing agency where customary.

The carrying amount of investments and other assets represents the maximum credit risk exposure as at the date of the Statement of Financial Position. The Fund may enter into securities lending transactions with counterparties and it may also be exposed to credit risk from the counterparties to the derivative instruments it may use. Credit risk associated with these transactions is considered minimal as all counterparties have a rating equivalent to a designated rating organization's credit rating of not less than A-1 (low) on their short-term debt and of A on their long-term debt, as applicable.

vii. Underlying funds

The Fund may invest in underlying funds and may be indirectly exposed to currency risk, interest rate risk, other price risk and credit risk from fluctuations in the value of financial instruments held by the underlying funds. Note 10 summarizes the Fund's exposure, if applicable and significant, to these risks from underlying funds.

9. Other Information

Abbreviations

Foreign currencies, if any, are presented in these financial statements using the following abbreviated currency codes:

Currency Code	Description	Currency Code	Description	Currency Code	Description
AUD	Australian dollars	HUF	Hungarian forint	PLN	Polish zloty
AED	United Arab Emirates Dirham	IDR	Indonesian rupiah	QAR	Qatar Rial
BRL	Brazilian real	ILS	Israeli shekel	RON	Romanian leu
CAD	Canadian dollars	INR	Indian rupee	RUB	Russian ruble
CHF	Swiss franc	JPY	Japanese yen	SAR	Saudi riyal
CZK	Czech koruna	KOR	South Korean won	SEK	Swedish krona
CLP	Chilean peso	MXN	Mexican peso	SGD	Singapore dollars
CNY	Chinese yuan	MYR	Malaysian ringgit	ТНВ	Thailand baht
COP	Colombian peso	NGN	Nigerian naira	TRL	Turkish lira
DKK	Danish krone	NOK	Norwegian krona	USD	United States dollars
EGP	Egyptian pound	NTD	New Taiwan dollar	VND	Vietnamese dong
EUR	Euro	NZD	New Zealand dollars	ZAR	South African rand
GBP	United Kingdom pounds	PEN	Peruvian nuevo sol	ZMW	Zambian kwacha
GHS	Ghana Cedi	PHP	Philippine peso		
HKD	Hong Kong dollars	PKR	Pakistani rupee		

INTERIM UNAUDITED FINANCIAL STATEMENTS | September 30, 2024

NOTES TO FINANCIAL STATEMENTS

- 10. Fund Specific Information (in '000, except for (a))
- (a) Fund Formation and Series Information

Date of Formation of the Predecessor Fund: October 28, 2002

Date of Formation of the Predecessor Fund is the start date of the applicable series of the Predecessor Fund, Mackenzie US Small-Mid Cap Growth Class, which was merged into the corresponding series of the Fund on July 30, 2021.

The Fund may issue an unlimited number of securities of each series. The number of issued and outstanding securities of each series is disclosed in the Statements of Changes in Financial Position.

Series Offered by Mackenzie Financial Corporation (180 Queen Street West, Toronto, Ontario, M5V 3K1; 1-800-387-0614; www.mackenzieinvestments.com)

Series A, Series T5 and Series T8 securities are offered to retail investors investing a minimum of \$500 (\$5,000 for Series T5 and Series T8). Investors in Series T5 and Series T8 securities also want to receive a monthly cash flow of 5% or 8% per year, respectively.

Series AR securities are offered to retail investors in a Registered Disability Savings Plan offered by Mackenzie.

Series D securities are offered to retail investors investing a minimum of \$500 through a discount brokerage or other account approved by Mackenzie.

Series F, Series F5 and Series F8 securities are offered to investors who are enrolled in a dealer-sponsored fee-for-service or wrap program, who are subject to an asset-based fee rather than commissions on each transaction and who invest at least \$500 (\$5,000 for Series F5 and Series F8); they are also available to employees of Mackenzie and its subsidiaries, and directors of Mackenzie. Investors in Series F5 and Series F8 securities also want to receive a monthly cash flow of 5% or 8% per year, respectively.

Series FB and Series FB5 securities are offered to retail investors investing a minimum of \$500. Investors are required to negotiate their advisor service fee, which cannot exceed 1.50%, with their financial advisor. Investors in Series FB5 securities also want to receive a monthly cash flow of 5% per year.

Series I securities are offered to retail investors investing a minimum of \$500 in a qualified group plan with a minimum of \$10,000,000 in assets. Investors in Series I securities also want to receive a monthly cash flow of 5% per year.

Series O securities are offered only to investors investing a minimum of \$500,000 who are enrolled in Mackenzie Portfolio Architecture Service or Open Architecture Service; certain institutional investors; investors in a qualified group plan, and certain qualifying employees of Mackenzie and its subsidiaries.

Series PW, Series PWT5 and Series PWT8 securities are offered through our Private Wealth Solutions to certain high net worth investors who invest a minimum of \$100,000. Investors in Series PWT5 and Series PWT8 securities also want to receive a monthly cash flow of 5% or 8% per year, respectively.

Series PWFB and Series PWFB5 securities are offered through our Private Wealth Solutions to certain high net worth investors who invest a minimum of \$100,000. Investors are required to negotiate their advisor service fee, which cannot exceed 1.50%, with their financial advisor. Investors in Series PWFB5 securities also want to receive a monthly cash flow of 5% per year.

Series PWR securities are offered through our Private Wealth Solutions to certain high net worth investors who invest a minimum of \$100,000 in a Registered Disability Savings Plan offered by Mackenzie.

Series PWX and Series PWX8 securities are offered through our Private Wealth Solutions to certain high net worth investors who invest a minimum of \$100,000. Investors are required to negotiate their advisor service fee, which cannot exceed 1.50%, with their financial advisor. Investors in Series PWX8 securities also want to receive a monthly cash flow of 8% per year.

Series UM securities are offered only to certain institutional investors.

Series B, Series J and Series M securities are no longer available for sale.

Series Distributed by LBC Financial Services Inc. (1360 René-Lévesque Blvd. West, 13th Floor, Montréal, Québec H3G 0A9; 1-800-522-1846; www.laurentianbank.ca/mackenzie)

Series LB securities are offered to retail investors investing a minimum of \$500.

Series LF securities are offered to retail investors investing a minimum of \$500, who are enrolled in the LBC Private Banking sponsored fee-for-service program.

Series LW securities are offered through our Preferred Pricing Program to certain high net worth investors who invest a minimum of \$100,000.

Effective June 1, 2022, an investor may purchase the Fund under a sales charge purchase option and a no-load purchase option. Not all purchase options are available under each series of the Fund. The sales charge under the sales charge purchase option is negotiated by the investor with their dealer. Securities purchased before June 1, 2022, under the redemption charge purchase option and low-load 3 purchase option (collectively the "deferred sales charge purchase options") may continue to be held in investor accounts. Investors may switch from securities of a Mackenzie fund previously purchased under these deferred sales charge purchase options to securities of other Mackenzie funds, under the same purchase option, until such time as the redemption schedule has expired. For further details, please refer to the Fund's Simplified Prospectus and Fund Facts.

INTERIM UNAUDITED FINANCIAL STATEMENTS | September 30, 2024

NOTES TO FINANCIAL STATEMENTS

- 10. Fund Specific Information (in '000, except for (a)) (cont'd)
- (a) Fund Formation and Series Information (cont'd)

nception/

Series	Reinstatement Date (1)	Management Fee	Administration Fee
Series A	November 8, 2002	2.00%	0.28%
Series AR	October 15, 2013	2.00%	0.31%
Series B	June 15, 2012	1.75%	0.31%
Series D	December 18, 2013	1.00%	0.20%
Series F	January 9, 2003	0.80%	0.15%
Series F5	October 16, 2017	0.80%	0.15%
Series F8	October 16, 2017	0.80%	0.15%
Series FB	October 26, 2015	1.00%	0.28%
Series FB5	October 24, 2018	1.00%	0.28%
Series I	December 18, 2002	1.35%	0.28%
Series J	February 17, 2011	1.75%	0.25%
Series M	November 8, 2002	Up to 1.00%	0.28%
Series 0	October 25, 2004	_ (2)	n/a
Series PW	October 17, 2013	1.80%	0.15%
Series PWFB	April 3, 2017	0.80%	0.15%
Series PWFB5	October 24, 2018	0.80%	0.15%
Series PWR	April 1, 2019	1.80%	0.15%
Series PWT5	April 3, 2017	1.80%	0.15%
Series PWT8	December 20, 2013	1.80%	0.15%
Series PWX	October 16, 2013	_ (3)	_(3)
Series PWX8	September 12, 2014	_ (3)	_(3)
Series T5	March 16, 2010	2.00%	0.28%
Series T8	July 27, 2010	2.00%	0.28%
Series UM	February 26, 2020	0.70%	0.15%
Series LB	January 26, 2012	2.00%	0.28%
Series LF	December 7, 2018	0.80%	0.15%
Series LW	December 1, 2017	1.80%	0.15%

⁽¹⁾ This is the inception date of the applicable series of Mackenzie US Small-Mid Cap Growth Class.

Expiration Date of Non-Capital Losses

		Total Non-Capital Loss \$	2030 \$	2031 \$	2032 \$	2033 \$	2034 \$	2035 \$	2036 \$	2037 \$	2038 \$	2039 \$	2040 \$	2041 \$	2042 \$	2043 \$
102	134	35,021	_	_	_	_	_	_	_	_	_	_	_	_	_	35,021

⁽²⁾ This fee is negotiable and payable directly to Mackenzie by investors in this series.

⁽³⁾ This fee is payable directly to Mackenzie by investors in this series through redemptions of their securities.

⁽b) Tax Loss Carryforwards

INTERIM UNAUDITED FINANCIAL STATEMENTS | September 30, 2024

NOTES TO FINANCIAL STATEMENTS

10. Fund Specific Information (in '000, except for (a)) (cont'd)

(c) Securities Lending

	September 30, 2024	March 31, 2024
	(\$)	(\$)
Value of securities loaned	145,431	11,114
Value of collateral received	153,315	11,694

	Septemb	er 30, 2024	Septembe	er 30, 2023
	(\$)	(%)	(\$)	(%)
Gross securities lending income	30	100.0	6	100.0
Tax withheld	_	_	_	_
	30	100.0	6	100.0
Payments to securities lending agent	(5)	(16.7)	(1)	(16.7)
Securities lending income	25	83.3	5	83.3

(d) Commissions

	(\$)
September 30, 2024	222
September 30, 2023	264

(e) Risks Associated with Financial Instruments

i. Risk exposure and management

The Fund seeks long-term capital growth and a reasonable rate of return by investing primarily in equities of small- to mid-capitalization U.S. companies. The Fund may also invest in equities of companies based outside of North America and in fixed income securities of U.S. and Canadian corporations and government bodies. *ii. Currency risk*

The tables below summarize the Fund's exposure to currency risk.

			Septem	ber 30, 2024				
					Impact on net assets			
Curronov	Investments (\$)	Cash and Short-Term Investments (\$)	Derivative Instruments (\$)	Net Exposure* (\$)	Strengthene (\$)	d by 5%	Weakened	l by 5%
Currency	(φ)	(φ)	(φ)	(φ)	(φ)	/0	(φ)	/0
USD	2,802,273	108,474	_	2,910,747				
Total	2,802,273	108,474	-	2,910,747				
% of Net Assets	96.3	3.7	-	100.0				
Total currency rate sens	sitivity				(145,537)	(5.0)	145,537	5.0

			Marc	th 31, 2024				
						Impact on r	et assets	
Currency	Investments (\$)	Cash and Short-Term Investments (\$)	Derivative Instruments (\$)	Net Exposure* (\$)	Strengthene	d by 5% %	Weakened	by 5% %
USD	2,958,589	110,533	_	3,069,122				
Total	2,958,589	110,533	_	3,069,122				
% of Net Assets	96.3	3.6	_	99.9				
Total currency rate ser	nsitivity				(153,456)	(5.0)	153,456	5.0

^{*} Includes both monetary and non-monetary financial instruments

iii. Interest rate risk

As at September 30, 2024 and March 31, 2024, the Fund did not have a significant exposure to interest rate risk.

INTERIM UNAUDITED FINANCIAL STATEMENTS | September 30, 2024

NOTES TO FINANCIAL STATEMENTS

- 10. Fund Specific Information (in '000, except for (a)) (cont'd)
- (e) Risks Associated with Financial Instruments (cont'd)

iv. Other price risk

The table below summarizes the Fund's exposure to other price risk.

	Increased by	10%	Decreased b	y 10%
Impact on net assets	(\$)	(%)	(\$)	(%)
September 30, 2024	280,227	9.6	(280,227)	(9.6)
March 31, 2024	295,859	9.6	(295,859)	(9.6)

v. Credit risk

As at September 30, 2024 and March 31, 2024, the Fund did not have a significant exposure to credit risk.

(f) Fair Value Classification

The table below summarizes the fair value of the Fund's financial instruments using the fair value hierarchy described in note 3.

		Septembe	r 30, 2024			March 3	31, 2024	
	Level 1 (\$)	Level 2 (\$)	Level 3 (\$)	Total (\$)	Level 1 (\$)	Level 2 (\$)	Level 3 (\$)	Total (\$)
Equities	2,802,273	_	_	2,802,273	2,958,589	_	_	2,958,589
Total	2,802,273	_	_	2,802,273	2,958,589	_	_	2,958,589

The Fund's policy is to recognize transfers into and transfers out of fair value hierarchy levels as of the date of the event or change in circumstances that caused the transfer.

During the periods, there were no transfers between Level 1 and Level 2.

(g) Investments by the Manager and Affiliates

The investments held by the Manager, other funds managed by the Manager, and funds managed by affiliates of the Manager, investing in series CL, IG or S of the Fund, as applicable (as described in *Fund Formation and Series Information* in note 10), were as follows:

	September 30, 2024	March 31, 2024
	(\$)	(\$)
The Manager	1,317	1,261
Other funds managed by the Manager	_	_
Funds managed by affiliates of the Manager	_	_

(h) Offsetting of Financial Assets and Liabilities

As at September 30, 2024 and March 31, 2024, there were no amounts subject to offsetting.

(i) Interest in Unconsolidated Structured Entities

As at September 30, 2024 and March 31, 2024, the Fund had no investments in Underlying Funds.